EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Study on the Active Constituents and Underlying Mechanisms of Renshen Yangying Decoction Against Angina Pectoris Based on Integrated Serum Pharmacochemistry, Network Pharmacology, Molecular Docking, and Experimental Validation

Ya Huang, Tao Xiong, Haixia Qiu, Rui Cheng, Yule Luo, Xingdong Wu iD

Journal of Analytical Methods in Chemistry · 2026-01 · 2026 (1)

DOI: 10.1155/jamc/6325730 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Analytical Methods in Chemistry, online erschienen am 03.11.2026. Verfasst von Ya Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jinsha County Chinese Medicine Hospital Jinsha Guizhou 551800 China. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aims to elucidate the pharmacological basis and underlying molecular mechanisms of Renshen Yangying decoction (RYD) in alleviating angina pectoris.

Methods

UHPLC–Q‐TOF‐MS was used to profile chemical constituents in RYD and RYD‐medicated serum. Compound identification was performed using a custom database, literature, reference standards, and the GNPS platform. Network pharmacology predicted disease‐related targets and pathways, followed by molecular docking and in vitro AC16 cardiomyocyte assays for validation.

Results

A total of 179 constituents in the decoction and 37 absorbed prototype compounds (mainly flavonoids, organic acids, alkaloids, and coumarins) were identified. 282 shared targets with angina were obtained, yielding 10 core targets (e.g., AKT1, TNF, BCL2, STAT3, and EGFR). Four main compounds (naringenin, schisantherin B, schisandrol A, and quercetin) were predicted to modulate EGFR, IGF‐1R, and PDGFR‐β pathways. Naringenin was experimentally confirmed to alleviate pathological damage by suppressing inflammatory responses.

Conclusion

RYD exerts antiangina effects through a multicomponent, multitarget, multipathway mechanism involving EGFR, PI3K–Akt, and PDGFR‐β signaling, with naringenin, schisantherin B, schisandrol A, and quercetin as major active constituents. These findings provide mechanistic insights supporting the clinical application of RYD.

Schlagwörter

Stichwörter der Autor:innen

Renshen Yangying decoction (RYD)active constituentsangina pectorismechanism of actionnetwork pharmacologyserum components

Autor:innen und Institutionen

  • Jinsha County Chinese Medicine Hospital Jinsha Guizhou 551800 China.
  • School of Pharmacy Zunyi Medical University Zunyi Guizhou 563000 China zmc.edu.cn.

ORCID-Profile: Xingdong Wu

Zitieren

APA

Huang, Y., Xiong, T., Qiu, H., Cheng, R., Luo, Y., & Wu, X. (2026). Study on the Active Constituents and Underlying Mechanisms of Renshen Yangying Decoction Against Angina Pectoris Based on Integrated Serum Pharmacochemistry, Network Pharmacology, Molecular Docking, and Experimental Validation. Journal of Analytical Methods in Chemistry, 2026(1). https://doi.org/10.1155/jamc/6325730

Vancouver

Huang Y, Xiong T, Qiu H, Cheng R, Luo Y, Wu X. Study on the Active Constituents and Underlying Mechanisms of Renshen Yangying Decoction Against Angina Pectoris Based on Integrated Serum Pharmacochemistry, Network Pharmacology, Molecular Docking, and Experimental Validation. Journal of Analytical Methods in Chemistry. 2026;2026(1). doi:10.1155/jamc/6325730

BibTeX
@article{Huang2026,
  author = {Huang, Ya and Xiong, Tao and Qiu, Haixia and Cheng, Rui and Luo, Yule and Wu, Xingdong},
  title = {Study on the Active Constituents and Underlying Mechanisms of Renshen Yangying Decoction Against Angina Pectoris Based on Integrated Serum Pharmacochemistry, Network Pharmacology, Molecular Docking, and Experimental Validation},
  journal = {Journal of Analytical Methods in Chemistry},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jamc/6325730}
}
Kostenlos starten →